Avelumab and Merkel Cell Carcinoma: Examining the Scientific Evidence
From General Health Surveillance to Occupational Exposure Concerns
The legacy of general health and science information has long emphasized population-level wellness, preventive behaviors, and broad environmental factors. This heritage, grounded in continuous data collection and evaluation, established standard definitions for health outcomes and the timely dissemination of findings. Such frameworks were designed to monitor community health trends, from nutritional status to occupational safety, without delving into specific disease mechanisms. As this foundation matured, it became evident that general health surveillance could not fully address the nuanced exposures encountered in specialized work environments. The transition from population-wide metrics to targeted occupational health concerns required a shift in focus—from broad lifestyle factors to specific chemical and pharmaceutical agents encountered in industrial settings. This pivot acknowledges that certain work-related exposures demand more granular investigation, particularly when novel therapeutic compounds enter production lines. Within this context, the occupational exposure concern arises: workers involved in the manufacturing or handling of biologic agents may face unique risks that general health surveillance was not designed to capture. The bridge between legacy public health frameworks and contemporary occupational medicine thus lies in applying rigorous data collection methods to specific workplace exposures, such as those involving immunomodulatory drugs.
Bridging to Avelumab: A Therapeutic Agent in Occupational Settings
This transition sets the stage for examining how scientific evidence connects such exposures to potential health outcomes, without presuming causation or mechanism. Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It is approved in the USA, the EU, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/). Avelumab was the first therapeutic agent specifically approved for this indication, and its approval was based on the two-part, single-arm, phase II trial JAVELIN Merkel 200, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/29799096/).
Scientific Evidence: Avelumab as Treatment, Not Cause
Merkel cell carcinoma is a rare, highly aggressive skin cancer with neuroendocrine differentiation, and its incidence is increasing (https://pubmed.ncbi.nlm.nih.gov/35877101/). The disease is associated with chronic exposure to ultraviolet light and the Merkel cell polyoma virus, and it carries high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Immune checkpoint inhibitors, including avelumab, have significantly improved treatment outcomes in metastatic disease, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). However, despite these advances, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). The scientific evidence connecting avelumab to Merkel cell carcinoma is primarily in the context of its use as a treatment for the disease, not as a causative agent. Avelumab is indicated for the treatment of metastatic MCC, and the literature consistently describes it as a therapeutic intervention rather than a trigger for the malignancy. For example, studies report on the activity of ipilimumab plus nivolumab in avelumab-refractory MCC, indicating that avelumab is used to treat patients who have already been diagnosed with MCC (https://pubmed.ncbi.nlm.nih.gov/33439294/). Similarly, a multicenter study of the prospective skin cancer registry ADOREG examined ipilimumab plus nivolumab in avelumab-refractory MCC, further confirming that avelumab is administered to patients with established MCC (https://pubmed.ncbi.nlm.nih.gov/36450381/). A retrospective study of ipilimumab plus nivolumab in anti-PD-L1/PD-1 refractory MCC also notes that avelumab is one of two agents approved by the U.S. Food and Drug Administration for the treatment of advanced MCC (https://pubmed.ncbi.nlm.nih.gov/35877101/).
Mechanistic Pathways and Risk Context
Mechanistic pathways linking avelumab to MCC are not described in the evidence as causative. Instead, avelumab functions by blocking PD-L1, thereby enhancing the immune system's ability to attack cancer cells. This mechanism is the basis for its therapeutic effect in MCC. However, checkpoint inhibitors including avelumab are known to cause overactivation of the immune system, leading to immune-related adverse events (irAEs) (https://pubmed.ncbi.nlm.nih.gov/31543781/). One reported case describes hypercalcaemia due to reactivation of sarcoidosis during treatment with avelumab for metastatic MCC, which was managed with corticosteroids and allowed continuation of avelumab therapy (https://pubmed.ncbi.nlm.nih.gov/31543781/). This case illustrates that avelumab can trigger immune-related adverse events, but it does not indicate that avelumab causes MCC. Regarding risk considerations, the adequacy of warnings about avelumab and MCC must be evaluated in light of its approved indication. Avelumab is specifically approved for the treatment of metastatic MCC, and its prescribing information includes warnings about immune-related adverse events. However, the evidence does not suggest that avelumab causes MCC; rather, it is a treatment for the disease. For affected patients, causation-related considerations should focus on the known risk factors for MCC, such as ultraviolet light exposure and Merkel cell polyoma virus, rather than avelumab exposure. The timeline between avelumab exposure and documented harm is relevant only in the context of adverse events during treatment, such as immune-related reactions, which can occur during therapy. For example, the case of hypercalcaemia due to sarcoidosis reactivation occurred during avelumab treatment and resolved with corticosteroids (https://pubmed.ncbi.nlm.nih.gov/31543781/). There is no evidence in the provided snippets of avelumab causing de novo MCC or of a temporal relationship between avelumab administration and the development of MCC.
Summary of Evidence
In summary, the scientific evidence does not support a causal link between avelumab and the development of Merkel cell carcinoma. Instead, avelumab is an established treatment for metastatic MCC, with documented efficacy and a known safety profile that includes immune-related adverse events. The risk narrative should emphasize that avelumab is not a causative agent for MCC but rather a therapeutic option for patients already diagnosed with the disease.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
Does avelumab cause Merkel cell carcinoma?
No, the scientific evidence does not support a causal link between avelumab and the development of Merkel cell carcinoma. Avelumab is a treatment for metastatic MCC, not a cause.
What is the mechanism of avelumab in treating MCC?
Avelumab blocks PD-L1, enhancing the immune system's ability to attack cancer cells. This mechanism is therapeutic, not causative.
Are there any risks associated with avelumab treatment?
Yes, avelumab can cause immune-related adverse events (irAEs) such as hypercalcaemia due to sarcoidosis reactivation, but these are manageable and do not indicate causation of MCC.
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.